Jefferies analyst Roger Song raised the firm’s price target on Nektar (NKTR) to $69 from $2 and keeps a Buy rating on the shares after the company’s REZOLVE-AD study of investigational rezpegaldesleukin met all endpoints. This data update gives Jefferies further confidence in Rezpeg’s potential as a novel biologic with a strong efficacy and safety profile in an enormous disease space, the firm told investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar price target raised to $100 from $60 at BTIG
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data
- Nektar price target raised to $120 from $6.50 at H.C. Wainwright
- Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today?